Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Weighted Average and Diluted) (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$201.12 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 83700.9% to -$201.12 in Q4 2025 year-over-year; TTM through Dec 2025 was -$201.12, a 15612.67% decrease, with the full-year FY2025 number at -$1.09, up 14.84% from a year prior.
  • EPS (Weighted Average and Diluted) was -$201.12 for Q4 2025 at Iovance Biotherapeutics, down from -$0.33 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.24 in Q4 2024 to a low of -$201.12 in Q4 2025.
  • A 3-year average of -$18.63 and a median of -$0.42 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 46.67% in 2024, then crashed 83700.9% in 2025.
  • Iovance Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.45 in 2023, then skyrocketed by 46.67% to -$0.24 in 2024, then crashed by 83700.9% to -$201.12 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EPS (Weighted Average and Diluted) are -$201.12 (Q4 2025), -$0.33 (Q2 2025), and -$0.36 (Q1 2025).